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Chk1The suicide system TK/GCV is an enzyme/prodrug therapy that involves the transfer of the cDNA for the
herpes simplex virus thymidine kinase gene (TK) into tumor cells which then sensitizes the cells to the non-
toxic antiviral drug ganciclovir. Although extensively characterized, the suicide system TK/GCV conceals the
details of its mechanism of action. In order to shed some light on this issue, we conducted experiments
designed to identify key features of sensitive cells, as compared to cells that displayed reduced sensitivity to
TK/GCV. Cell lines displaying different degrees of sensitivity underwent apoptotic cell death upon treatment
with TK/GCV. S-phase delay, however, was almost exclusively restricted to sensitive cells and was impaired
in a model of treatment-induced resistance. In this model genes with differential expression associated to
induced resistance were identiﬁed. Noteworthy, two cell cycle-related genes (CCNE1 and GADD45) were
functionally validated as conditioners of cellular sensitivity to TK/GCV. The relevance of cell cycle control
was further demonstrated by experiments showing the association of Chk1 activation with greater TK/GCV
cytotoxicity. Combination treatment with Chk1 inhibitor UCN-01 induced, in sensitive cells, an antagonistic
effect on TK/GCV cytotoxicity highlighting the relevance of Chk1's activity on TK/GCV mechanism of action.
These results reveal the relevance of cell cycle control pathways in the cytotoxicity induced by the TK/GCV
system identifying candidate genes as conditioners of TK/GCV sensitivity. Moreover it points out, for the ﬁrst
time at Chk1 activation as a key factor to mediate TK/GCV cytotoxicity.ica, Dr. Aiguader, 88, 08003-
ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
Therapies based on in situ enzymatic activation of a systemically
administered non-toxic prodrug, into its cytotoxic metabolite, hold
the promise of presenting a broader therapeutic window than
conventional chemotherapeutic agents by achieving high doses of
the active compound restricted to speciﬁc tissue, thus allowing for
more aggressive interventions. This is particularly relevant for the
treatment of malignant diseases that are refractory to conventional
chemotherapy, such as pancreatic adenocarcinoma.
Among the so-called gene-directed prodrug enzyme-activated
therapies or suicide therapies, the one that combines the activating
enzymeHerpes simplex virus thymidine kinase (TK)with the prodrug
ganciclovir (GCV) remains by far the most extensively studied [1]
presenting promising results for the treatment of some malignant
conditions [2]. Nevertheless, details regarding its mechanism of
induction of cytotoxicity are yet to be disclosed.Previous studies havedocumented induction of apoptosis in response
to TK/GCV treatment, putatively triggered by the formation of Double
Strand Breaks (DSB), induced by the incorporation of phosphorylated
GCV, in cellular DNA [3]. Although it had been proposed that a p53-
dependent translocation of CD95was responsible of the induction of the
extrinsic pathway of apoptosis [4] later studies demonstrated that TK/
GCV induced mitochondrial apoptosis regardless of p53 status or Death
receptors [5,6].
S- or S-and G2/M-Phase arrest in cell cycle progression had also
been associated with response to TK/GCV in several cellular models
[3,5,7]. Nevertheless, whether these changes play a relevant role in
TK/GCV mechanism of action or are mere side events remains to be
clariﬁed.
In this studywehave analyzed, by using aﬁrst generation adenoviral
vector to express TK under a CMV promoter, the response to TK/GCV
treatment of a panel of a p53-deﬁcient cells derived from human
pancreatic adenocarcinoma. Our results show that sensitive and
resistant cells display differential properties in terms of cell cycle
control in a model of intrinsic resistance and in a model of treatment-
induced resistance. A comparative transcriptomic analysis has identiﬁed
a list of differentially expressed genes, some of which have been
validated as potential resistance-marker genes and a functional analysis
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out Checkpoint Kinase 1 (Chk1) as a relevant mediator of its
mechanism of action.
2. Materials and methods
2.1. Constructs
CCNE1 full-length clone (IRAUp969H0878D) and GADD45A EST
clone (IMAGp998l1012777Q) were purchased from ImaGenes GmbH
(Berlin, Germany). CCNE1 and GADD45A cDNAs were cloned into
pLXSN and pLHCx plasmids (Clontech, Saint-Germain-en-Laye,
France), to generate the expression vectors pL-CCNE1-SN and pLHC-
GADD45A, respectively.
2.2. Cell lines and transfection
Human pancreatic tumour cell lines BxPC-3 and PANC-1 were
obtained from the American Type Culture Collection (ATCC; Rockville,
MD). NP-9, NP-31 and NP-18 cells have been described elsewhere [8].
MIAPaca-2 and RWP-1 pancreatic cancer cell lines were kindly provided
by Dr F.X. Real. Cells lines were cultured as previously described [9,10].
Generation of NP-18AR cells: NP-18 cells were submitted to 4 rounds
of transductionwithAdTK and subsequent culturedwith 10 μgmL−1GCV
(Cymevene, Roche, Madrid, Spain). Viral doses were scaled up from 3 vp
mL−1, in the ﬁrst two transductions, to 150 vpmL−1 and 350 vpmL−1 in
the third and fourth transductions, respectively. GCV treatment was
applied during 12, 11, 27 and 15 days right after ﬁrst, second, third and
fourth transduction, respectively.
Transient transfection of RWP-1 and MIAPaca-2 cells was
performed using Lipofectamine2000 and PlusReagent (Invitrogen,
Barcelona, Spain) following manufacturer's instructions.
Retroviral particles were generated by calcium-phosphate DNA
precipitation transfection of retroviral vectors pL-CCNE1-SN, pLXSN,
pLHC-GADD45A or pLHCx into the Phoenix amphotropic packaging
cell line (ATCC; Rockville, MD). After 48 h the viral supernatant was
collected, passed through 0.45 μm ﬁlters and used for transduction.
BxPC-3 and NP-9 cells overexpressing GADD45A or cyclin E1,
respectively, and the corresponding control cells were obtained by
three consecutive rounds of retroviral transductionwith 2 ml of either
RvGADD45A or RvCH or RvCCNE1 or RvCSN virus-containing media in
the presence of 8 μg/ml polybrene (Sigma-Aldrich; Saint Louis, MI,
USA) for 16 h at 37 °C. Forty-eight hours after the third transduction,
cells were selected in either 200 μg/ml of Hygromicin or 800 μg/ml
G418 (Sigma; Saint Louis, MI, USA) for 7 days. Resistant clones were
pooled and used for subsequent experiments.
2.3. Adenoviral infection and ID50
Serotype 5 adenovirus encoding TK under the control of a CMV
promoter (AdTK) has been previously described [11].
Culture viability was measured and dose–response curves were
constructed for NP-9, NP-18, NP-31, PANC-1, MIAPaca-1, RWP-1 and
BxPC-3 transduced with AdTK and cultured with 10 μg mL−1 during
5 days as previously described [9]. ID50 values were estimated from
dose–response curves by standard non-linear regression, using an
adapted Hill Equation (GraFit v3.0, Erithacus Software, Surrey, UK).
2.4. Apoptosis induction
Induction of programmed cell death was assayed by monitoring
PARP cleavage or active caspase-3 in whole cell extracts by Western
blotting, using a puriﬁed mouse anti human PARP antibody (BD
Biosciences, San Jose, CA) or anti-cleaved caspase-3 (Cell Signaling
Technology; Danvers, MA, USA).2.5. Cell cycle analysis
Cells were trypsinized, counted and resuspended in complete
medium at a concentration of 1×106 cells mL−1. Hoechst 33342
(Sigma-Aldrich, Madrid, Spain) was added to a ﬁnal concentration of
5 μg mL−1 and mixture was incubated 1 h at 37 °C. DNA content was
measured in an LSR Flow Cytometer (BD Biosciences, San Jose, CA).
Quantiﬁcation of percentage of cells in each phasewas performed using
ModFit 3.0 LTTM Software (Verity Software, Topsham, ME).
2.6. RNA extraction and real-time RT-PCR analysis
Total RNAwas extractedwith TriPure reagent (Roche), and reverse
transcribed with Retroscript RT kit (Ambion, Austin, TX), using
random decamers, in accordance with the manufacturer's protocols.
Real-Time RT-PCR was performed using SYBRgreen (Roche) in a
capilaries LightCycler (Roche) thermal cycler. HPLC-puriﬁed primers
were purchased form Sigma-Aldrich. Primer sequences are described
in Supplementary Table I. Statistical analysis of relative expression of
genes was performed by pair wise ﬁxed reallocation randomization
test using the Relative Expression Software Tool (REST©) [12,13].
2.7. Microarray analysis
Cyanine 3- or Cyanine 5-labeled cRNA probes were synthesized
using the Agilent Low RNA Input Fluorescent Linear Ampliﬁcation Kit
(Agilent, Las Rozas, Spain), according to manufacturer's recommenda-
tions. Probes were mixed in hybridization buffer (In situ Hybridization
Kit Plus, Agilent) and two-color competitive hybridizations were
performed in 60mer oligonucleotide microarrays (H22K, Las Rozas,
Spain) during 18 h at 60 °C. Fluorescent images were obtained using an
Agilent G2565BA scanner at 100% PMT 100% laser power settings and
quantiﬁed through the GenePix 6.0 software (Axon, Molecular Devices,
Sunnywale, CA) using the irregular feature ﬁnding option.
Extracted raw data were ﬁltered and normalized using the Limma
package developed within the Bioconductor project in the R statistical
programming environment [14]. Target genes were considered as
differentially expressed when above the 95% rank in the B empirical
Bayes statistic and above a set fold change of 1.2. All quantitative and
statistical analyses were performed using Limma package in the R
environment [15], Lowess-normalized log2 ratio representing resistant
versus sensitive cells. (Data available in GEO, accession number
GSE17137).
2.8. Western blotting
Nuclear extracts were prepared using a protocol adapted from Ref.
[16]. Whole-cell extracts for the detection of P-Chk1/2 were prepared
by lysing the scrapped cells with a modiﬁed RIPA buffer. For the
detection of histone gamma-H2AX and active caspase-3 cellswere lysed
in hot sodium-dodecyl sulfate (SDS) sample buffer as described [17].
All protein extracts were quantiﬁed using BCA kit (Promega,
Madrid, Spain). SDS-PAGE and Western blot experiments were
performed following standard protocols and developed using En-
hanced Chemoluminescence Kit (Amersham).
Antibodies against Phospho-Chk1 (Ser 345) (133D3) and Phospho-
Chk2 (Thr 68) were purchased from Cell Signaling (Danvers, MA).
Antibody against Cdc25A (clone DC5120) was purchased from Upstate
(Temecula, CA). Antibodies for the detection of Chk1 (G-4) sc-8408, Chk2
(H-300) sc-9064, GADD45a (H-165, sc-797, rabbit polyclonal), Lamin B1
(H-90, sc-20682, rabbit polyclonal), and Cyclin E (HE12, sc-247, mouse
monoclonal)werepurchased fromSantaCruzBiotechnology (Heidelberg,
Germany). As loading controls antibodies anti-α-tubulin (T9026, mouse
monoclonal, Sigma-Aldrich, Madrid, Spain) and anti-GAPDH (MAB 374,
mouse monoclonal, Millipore, Temecula, CA) were used. Secondary
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rabbit-anti-mouse secondary antibodies (DAKO, Glostrup, Denmark).
2.9. Immunocytochemistry
Histone gamma-H2AXwas detected using the Anti-phosphoHistone
H2A.X (ser139) antibody, clone JBW301 (Millipore, Temecula, CA).
Brieﬂy, cells were treated as indicated in each case, then rinsed twice
with TBS, ﬁxed with ethanol:acetic acid 95:5 during 5 min, and blocked
with 3% BSA TBS. Incubation with 2 μg mL−1 primary antibody was
performed in blocking buffer during 1 h. Alexa-488-conjugated sec-
ondary antibody was incubated during 1.5 h at 1/400 (Alexa488 anti
Mouse, Dako, Glostrup, Denmark). Images were acquired in a Zeiss
Observer microscope, using the AxioVision 4.7.1 software (Carl-Zeiss).
2.10. DNA synthesis
DNA synthesis was measured using the Click-iT™ EdU Flow
Cytometry Assay (Invitrogen), based on the incorporation of a
nucleoside analogue (EdU) that can be ﬂuorescently marked. Samples
were acquired in a FACScan ﬂow cytometer.
2.11. Combination index
The induction of synergism, summation or antagonism between
UCN-01 and TK/GCV treatments was analyzed by Combination Index
analysis as previously described [18]. Dose–response curves were
constructed for the treatment with either UCN-01, TK/GCV or a
combination of both, fromwhich Hill coefﬁcient and ID50 values were
calculated by non-linear regression based on a modiﬁed Hill Equation
using the GraFit v3.0 software. Estimated equation was used to
calculate the doses of each treatment, administered independently or
in combination, necessary to induce a fractional inhibition (FI) of 10%,
20%, 30%, 40%, 50%, 60%, 70%, 80% and 90%.
CI(FI)=DAdTK,UCN01/DAdTK+DUCN01,AdTK/DUCN01, where CI(FI) is the
combination index for a given FI; DAdTK,UCN01 is the dose of AdTK/GCV
needed to produce given FI when applied in combination with
UCN01; DAdTK is the dose of AdTK/GCV needed to produce a given FI
when applied alone; DUCN01,AdTK is the dose of UCN-01 needed to
produce given FI when applied in combination with AdTK/GCV; and
DUCN01 is the dose of UCN-01 needed to produce a given FI when
applied alone. CI=1 indicates additivity, CIb1 indicates synergism
and CIN1 indicates antagonism between treatments.
3. Results
3.1. Differential cellular response to AdTK/GCV
NP-9, NP-18, NP-31, BxPC-3, MIAPaca-2, PANC-1 and RWP-1
pancreatic cancer-derived cell lines were transduced at increasing doses
of AdTK and subsequently treated with 10 μg mL−1 GCV during 5 days.
Dose–response curves were generated (Fig. 1A), allowing the estimation
of the InhibitoryDose50%(ID50)using anon-linear regressionmodel. This
parameter was used to classify cells as sensitive cells (NP-18, BxPC-3 and
RWP-1) or as resistant cells (NP-9, NP-31, MIAPaca-2 and Panc-1), being
the ID50 values from the latter group 32 to 264 times higher than those of
the former (Fig. 1B). These cells are known to display variable
susceptibility to adenoviral infection [9] so, in order to rule out the
possibility that differences in ID50 values were due exclusively to
differences in infectivity, TK mRNA levels were analyzed by RT-PCR after
transductionof eachcell line at aviral dose equivalent to its ID50. TKmRNA
levels of any given resistant cell line were higher than those of every
sensitive cell line (Fig. 1C). Taking into account that, in this experimental
setting, the cytotoxic effect induced in both sensitive and resistant cells
was quantitatively the same (50% inhibition in culture viability), the
observation that a higher expression of TKmRNAwas necessary to inducethis effect suggested that theremight be othermechanism(s) causing this
differential response, apart from infectivity.
Time-course PARP cleavage analysis revealed that TK/GCV
treatment induced apoptosis, when cells were transduced at a viral
dose equivalent to their respective ID50 and treated with 10 mg mL−1
GCV, in all but NP-9 cells. The low molecular weight form of PARP
appear around day 3 of treatment, becoming the most abundant form
in NP-18 cells at day 5 (Fig. 1D). The lack of apoptotic response in NP-9
cells was also observed by the quantitative assay Annexin V-FITC/
Propidium Iodide staining (Supplementary Fig. 1). To further conﬁrm
the apoptotic induction we analyzed activation of caspase-3. Cleaved
caspase-3 was observed in all the cell lines, and was already
detectable at 24 h in BxPC-3 and MIAPaCa-2 cells and at day 3 in
the rest of cell lines (Fig. 1D). The presence of active caspase-3 in NP-9
but the lack of PARP-cleavage and Annexin-V positive cells might be
eventually related to a delay on the apoptotic cascade in this cell line.
In fact caspase activation precedes phoshatydil serine exposure,
measured in the annexin binding assay and active caspase-3 will
execute later on PARP cleavage.
Time-course cell cycle analysis of the each cell line upon exposure
to AdTK/GCV at isotoxic doses (i.e., each cell line at its own ID50 value)
showed that sensitive cell lines presented an increase in the
percentage of cells in S-phase (NP-18 and BxPC-3) or S- and G2/M-
phase arrest (RWP-1), while these changes were less evident or even
null in all resistant cells but MIAPaca-2 (Fig. 1E and F). These results
suggest that cell cycle events might be inﬂuencing TK/GCV response.
3.2. Gene expression patterns associated with susceptibility to TK/GCV
In order to identify genomic and/or molecular features that might
condition the cellular response to the treatment, we ﬁrst evaluated
the differential expression of genes between resistant and sensitive
cells, in a treatment-induced resistance model. Three NP-18 derived
cell lines were independently generated by repeated exposures to
AdTK/GCV, and named NP-18AR1, NP-18AR2 and NP-18AR3, display-
ing ID50 values of 32.76 vp cell−1, 69.67 vp cell−1 and 49.82 vp cell−1
(this is, 4.8-, 10.4- and 7.4-fold higher than that of parental NP-18
cells), respectively (Fig. 2A). Differences in infectivity did not account
for the differences in sensitivity as the amount of TK transcript
necessary to attain a 50% inhibition in cell culture viability was higher
for NP-18AR cells (3.69 times for NP-18AR1, pb0.01; 10.70 times for
NP-18AR2, pb0.01; 5.61 times for NP-18AR3, pb0.01) than for
parental NP-18 cells.
Time-course cell cycle analysis ofNP-18andNP-18AR transducedwith
AdTK cells revealed that, although not completely abrogated, S-phase
delay was less evident in NP-18AR cells than in parental cells. Percentage
of parental NP-18 cells in S-phase (70.0%) was signiﬁcantly higher that
that of NP-18AR1 (60.7%, p=0.008), NP-18AR2 (60.5%, p=0.014) and
NP-18AR3 (60.8%, p=0.021) (Fig. 2B).
3.3. Transcriptome analysis
In order to analyze the changes in gene expression associated to the
different response to TK/GCV between NP-18 and NP-18AR cells, each
cell linewas transducedwithAdTK at 20 vp cell−1 and then treatedwith
10 μgmL−1GCVduring3 days. This experimental settingwas conceived
to screen for differences in gene expression between sensitive and
resistant cells in response to treatment rather than in basal conditions.
NP-18AR1, NP-18AR2 and NP-18AR3 were treated separately and used
as biological replicates. At day 3, cells were harvested and RNA was
extracted and used as a template to synthesize ﬂuorescently labeled
cRNA. A total of 9 competitive hybridizationswere performed in Agilent
22K oligonucleotide arrays (two NP-18AR1 vs. NP-18; four NP-18AR2
vs. NP-18; three NP-18AR3 vs. NP-18) including dye-swapped technical
replicates. Four hundred sixty nine differentially expressed genes were
identiﬁed (Supplementary Table 1). Within the whole population of
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Fig. 2. Treatment-induced resistancemodel. (A) Dose–response analysis of parental NP-18 and resistant NP-18AR1, NP-18AR2 and NP-18AR3 cells. (B) Cell cycle proﬁling of sensitive
and resistant cells in response to AdTK/GCV at 20 vp cell−1 and 10 μgmL−1 GCV. Time course and endpoint analysis at day 3 (bars diagram) showed that treatment-induced S-phase
accumulation was milder in resistant cells. *pb0.05. Endpoint results shown as mean of three independent experiments±SE. (C and D) Statistically signiﬁcant overrepresented
categories of genes with differential expression, obtained by EASE (C) and IPA (D) analyses.
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nucleosome were signiﬁcantly overrepresented (p=0.0112 and
0.0226, respectively), as well as genes involved in nucleosome and
chromatin assembly (p=0.0135 and 0.0191, respectively) (Fig. 2C).
Genes involved in pathways related to cancer (p=6.62×10−23); cell
death (1.69×10−21); gene expression (3.78×10−17); cellular growth
and proliferation (1.67×10−15); cell cycle (4.57×10−11); DNA replica-
tion, recombination and repair (3.72×10−5); cellular function and
maintenance (1.12×10−3) and tumor morphology (6.10×10−3) were
also found to be overrepresented (Fig. 2D).
Validation of microarray results was performed by real-time RT-PCR
on six genes. Differential expression was conﬁrmed for up-regulated
genes (GPC-4, NMU, GADD45A, POLK) and down-regulated genesFig. 1. Pancreatic cancer cells' response to TK/GCV. (A) Dose–response analysis. Brieﬂy, c
overnight. Twenty-four hours later, cells were infected with AdTK, using a dose range of 0
complete medium supplemented with 10 μg mL−1 GCV. Viability was measured 5 days late
pancreatic cancer cells transduced with AdTK each at their respective ID50. TK mRNA leve
**pb0.01. (D) Apoptosis induction by TK/GCV. Each cell line was transduced with AdTK at its
in a daily fashion by Western blot. Cleaved Caspase-3 was analyzed at the indicated time-poi
analysis of cell cycle proﬁles in cells transduced with AdTK at isotoxic doses (ID50) and trea
observed in all sensitive cells treated with AdTK/GCV (F) but not in resistant cells except fo(CCNE1, GPC3). Noteworthy, the fold change of GADD45A and POLK
calculated by RT-PCR doubled those obtained in the microarray
experiment. (Table 1).
3.4. Functional validation of CCNE1 and GADD45A
We next evaluated a possible causal relationship between the
deregulation of two cell cycle-related genes, CCNE1 and GADD45A, and
the decrease in cellular sensitivity to TK/GCV. Resistant MIAPaca-2 cells
were transiently transfected with pLCCNE1SN or pLXSN (control)
plasmids and resistant NP-9 cells were retrovirally transduced with Rv-
CCNE1 or Rv-CSN (control) particles obtaining in the two cell lines an
increase in cyclin E expression (Fig. 3A) Viability measurements afterells were seeded in 96-well plates at a density of 3×103 cells per well and cultured
to 3×106 vp cell−1, in triplicates. Four hours post-infection medium was replaced by
r by MTT. (B) ID50 values±Standard Error. *pb0.05. (C) Relative expression of TK in
ls in resistant cells were higher that those of sensitive cells at isotoxic doses of AdTK.
own ID50, and treated with 10 μgmL−1 GCV during 5 days. PARP cleavage was analyzed
nts by western blot. GAPDH was used as internal loading control. (E and F) Time course
ted with GCV or control cells receiving GCV alone. Accumulation of cells in S-phase was
r MIAPaca-2 (E).
Table 1
RT-PCR validated genes.
Symbol Gene name Fold change
array
Fold change
RT-PCR
GPC4 Glypican 4 4.30 5.05
NMU Neuromedin U 3.95 3.49
GADD45A Growth arrest and DNA-damage
inducible, alpha
1.47 3.46
POLK DNA Polymerase kappa 1.45 3.45
CCNE1 Cyclin E1 −1.69 −1.68
GPC3 Glypican 3 −3.44 −4.46
1180 D. Abate-Daga et al. / Biochimica et Biophysica Acta 1803 (2010) 1175–1185AdTK/GCV exposure revealed a decrease of 20% in the ID50 ofMIAPaca-2
cells and of 7-fold in NP-9 cells overexpressing cyclin E as compared to
controls (MIAPaca-2 pLXSN=311.75±13.75 vp/cell; MIAPaca-2
pLCCNE1SN=247.51±17.07 vp/cell) (NP-9 RvCSN=3796.79±
1265.77 vp/cell; NP-9 RvCCNE1=564.92±35.95 vp/cell) (Fig. 3C).Fig. 3. Functional validation of CCNE1 and GADD45 inﬂuence in tumor cell sensitivity to T
transfected with pLX-CCNE1-SN or pLXSN as a control and in NP-9 cells retrovirally transduc
RWP-1 cells transiently transfected with pLHC-GADD45A or pLHCx as a control and in BxPC
AdTK/GCV inMIAPaca-2 and NP-9 overexpressing cyclin E and control cells. *pb0.05. (D) ID5
*pb0.05. (E and F) Real-time RT-PCR analysis of GADD45Abasal (E) and induced (F)mRNA ex
expression. *pb0.05, **pb0.01.On the other hand, TK/GCV-sensitive RWP-1 cells transfected with
pLHCGADD45A or BxPC-3 cells transducedwith RvGADD45A presented
a marked overexpression of GADD45A, as compared to RWP-1
transfected with the empty plasmid pLHCx or to BxPC-3 transduced
with the control virus RvCH (Fig. 3B). An increase of about 25% in its
ID50 value for TK/GCV was obtained in RWP-1 cells (RWP-1
pLHCx=30.38±1.11; RWP-1 pLHCGADD45A=37.10±2.02) and of
7-fold in BxPC-3 cells (BxPC-3 RvCH=15.13±3.95 vp/cell; BxPC-3
RvGADD45A=107.16±35.95 vp/cell) (Fig. 3D), recapitulating the
phenotype displayed by NP-18AR cells, in which GADD45A expression
was increased when compared to NP-18 cells.
In order to evaluate whether differential expression of CCNE1 and
GADD45A could explain differences in intrinsic sensitivities to TK/
GCV between cell lines, mRNA levels of CCNE1 and GADD45A were
measured by real-time RT-PCR, in NP-9, NP-18, NP-31, BxPC-3,
MIAPaca-2, PANC-1 and RWP-1 cells, both in basal state and in
response to TK/GCV treatment. Basal GADD45A mRNA expression inK/GCV. (A) Western blot analysis of cyclin E expression in MIAPaca-2 cells transiently
ed with RvCCNE1 or RvCSN control. (B)Western blot analysis of GADD45A expression in
-3 cells retrovirally transduced with RvGADD45A or RvCH control. (C) ID50 values for
0 values for AdTK/GCV in RWP-1 and BxPC-3 overexpressing GADD45A and control cells.
pression. (G andH) Real-time RT-PCR analysis of CCNE1 basal (G) and induced (H)mRNA
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BxPC-3 the only cell line presenting a signiﬁcantly higher expression
(pb0.01). (Fig. 3E). GADD45A mRNA expression was induced in all
seven cell lines when they were treated with AdTK/GCV at isotoxic
doses (pb0.01). Notably, induction was higher in resistant cells
(pb0.05). (Fig. 3F). CCNE1 basal expression was signiﬁcantly lower in
NP-9, NP-31, BxPC-3 and MIAPaca-2 cells when compared to NP-18
cells (pb0.01) (Fig. 3G0.01) but no association between TK/GCV
sensitivity and intensity of regulation was found (Fig. 3H).
3.5. Checkpoint activation in response to TK/GCV treatment
Given that S- or S- and G2/M-phase delay seemed to correlate
with cellular sensitivity to TK/GCV, we sought to determine whether
the key elements governing S-phase checkpoint activation might play
a relevant role in the mechanism of action of TK/GCV. Histone H2A.X
phosphorylation was monitored as an indicator of activation of
kinases ATM and/or ATR. Western blot analysis showed a time-
dependent increase in the phosphorylated form of H2A.X in NP-18
cells treated with AdTK/GCV, starting at 24 h of treatment and
reaching a maximum at 72 h (Fig. 4A). The formation of H2A.X foci
was evident at 48 h post-treatment (Fig. 4B).
ATR and ATM activate two different yet partially overlapping
signaling pathways, which converge in the inhibitory phosphorylation
of Cdc25A triggering its proteasomal degradation. Western blot
analysis of Cdc25A expression showed a decrease in protein levels
2–3 days after the initiation of the treatment with TK/GCV, suggesting
the participation of either cascade in TK/GCV-induced cell cycle proﬁle
alterations (Fig. 4C).
3.6. ATR-Chk1 vs. ATM-Chk2
The ATR-Chk1 axis is conventionally associated to a response to
genotoxic insults involving DNA synthesis inhibition, while the ATM-
Chk2 axis is mainly activated by Double Strand Breaks (DSB) [19].
Given that TK/GCV has been described to induce both DNA synthesis
inhibition [20] and DSB [3] we sought to determine whether either
pathway was preferentially activated. To this end, phosphorylation of
Chk1 (S345) and Chk2 (Thr68) was monitored by Western blot in
time course experiments. Sensitive NP-18 cells were treated with
AdTK/GCV during 3 days, and cellular extracts were prepared everyFig. 4. DNA damage detection and checkpoint activation. (A) Time course Western blot ana
cells upon treatment with 300 vp/cell AdTK and 10μg mL−1 GCV. Scale bar, 20 μm. (C) Time
cell AdTK and 10 μg mL−1 GCV.12 h. Chk1 phosphorylation was evident as soon as 12 h after the
initiation of the treatment, while P-Chk2(Thr68) levels increased after
36 h (Fig. 5A). This result was conﬁrmed by immunoﬂuorescence
(Supplementary Fig. 2). To conﬁrm these differences in the kinetics of
Chk1 and Chk2 phosphorylation, phosphoprotein levels were
assessed at 0, 0.5, 1, 2, 4, 8 and 24 h of treatment with AdTK/GCV.
Results show that Chk1 phosphorylation started as soon as 30 min of
treatment, while Chk2 phosphorylation was not detected within this
time range (Fig. 5B). Both Chk1 and Chk2 phosphorylation preceded
PARP cleavage (Fig. 5C and D). Chk1 phosphorylation was also
detected in the BxPC-3 sensitive cell line and in MIAPaCa-2 cells but
not in the resistant NP-9 cells, suggesting that this event might be
associatedwith the S-phase cell cycle arrest observed in sensitive cells
and in MIAPaCa-2 resistant cells (Fig. 5E). In MIAPaCa-2 cells a loss of
total Chk1 protein was observed at day 3, andmay be attributed to the
activation-mediated degradation of Chk1. Total Chk1 degradation in
MIAPaCa-2 cells has been previously demonstrated to occur in
response to cytotoxic doses of gemcitabine [21].3.7. Chk1 as a key effector in the mechanism of TK/GCV cytotoxicity
To further test the potential association between CHK1 phosphor-
ylation and TK/GCV sensitivity, we evaluated the effect of the
pharmacological inhibition of Chk1 enzymatic activity on S-phase
checkpoint activation in response to TK/GCV. UCN-01 (or 5-OH-
staurosporine, Sigma-Aldrich)'s ability to inhibit Chk1's (but not
Chk2's) kinase activity was used to evaluate the participation of Chk1
in treatment-induced S-Phase arrest. NP-18 cells were treated with
either 6 vp/cell or 300 vp/cell AdTK plus GCV in combination with
300 nM UCN-01 during 3 days and DNA content was analyzed at the
indicated time points (Fig. 6A). While AdTK/GCV treatment induced
an increase in S-phase population, in detriment of G0/G1 population,
both at high and low doses, combination with UCN-01 resulted in an
inhibition of such increase in S-phase cells and inmaintenance of high
percentage of cells in G0/G1.
In order to test whether this increased population of cells in S-
phase was indeed arrested in its progression in cell cycle, we
measured the rate of DNA synthesis during a time window of 24 h
that started when cells had been treated with AdTK/GCV during 24 h.
DNA synthesis, expressed as percentage of EdU-positive cells, was
decreased in NP-18 cells treated with AdTK/GCV as compared tolysis and (B) immunoﬂuorescent detection of histone H2A.X phosphorylation in NP-18
course Western blot analysis of Cdc25A abundance in NP-18 cells treated with 300 vp/
Fig. 5. Chk1 and Chk2 phosphorylation. (A) Time course Western blot analysis of nuclear extracts of NP-18 cells treated with AdTK/GCV. Chk1 and Chk2 were phosphorylated in a
time-dependent manner, without changes in total Chk1 levels. (B) Chk1 phosphorylation started as soon as 30 min after establishment of treatment, whereas phosphorylation of
Chk2 was not evident within a time frame of 24 h. (C and D) PARP cleavage assay showing that phosphorylation of Chk1 and Chk2 started before induction of apoptosis. (E) Time
course Western blot analysis of whole cell extracts of sensitive BxPC-3 and resistant NP-9 and MIAPaca-2 cells treated with AdTK/GCV.
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(pb0.01) indicating that these cells had a lower DNA synthesis rate,
most likely due to the activation of the S-phase checkpoint.
Combination treatment with UCN-01, starting 24 h after initiation of
AdTK/GCV treatment, reverted AdTK/GCV-induced reduction in DNA
synthesis (pb0.01) restoring control levels (Fig. 6B).
3.8. Effects of checkpoint inhibition on cellular sensitivity to TK/GCV
The relevance of Chk1-mediated S-phase activation as a part of the
mechanism of action of TK/GCV was further explored by analyzing the
changes in sensitivity to TK/GCV, induced by UCN-01 in a panel of
pancreatic cancer cell lines. To this end, pharmacological interaction
between the above-mentioned treatments was assessed by Combina-
tion Index analysis (CI) in NP-9, NP-18, NP-31, BxPC-3, MIAPaca-2,
PANC-1 and RWP-1. CIwas calculated for each cell line and for 10%, 20%,
30%, 40%, 50%, 60%, 70%, 80 and 90% fractional inhibition. Whereas CI
values forNP-9 andNP-31 resistant cellswerehigher than1, indicating a
potentiation of AdTK/GCV when combined with UCN-01, CI values for
resistant PANC-1 cells lied in the close vicinity of the additivity line
(Fig. 7A) and, more interestingly, CI values for resistantMIAPaca-2 cells
and sensitive NP-18, BxPC-3 and RWP-1 cells were higher than 1
(Fig. 7B), indicating that cells arresting in S- or S- and G2/M-phase in
response to TK/GCV, the inhibition of checkpoint by UCN-01 induces an
antagonistic effect in terms of treatment-induced cytotoxicity.
4. Discussion
The vast majority of cancer cells present an altered p53 pathway,
thus relying on alternative pathways to respond to genotoxic insults.
Being DNA damage induction the cornerstone of many anticancer
strategies, it is expected that the mechanisms involved in tumor cell
response to such damagewill condition the outcome of the antitumoral
therapy. Tumor cells havebeendescribed toundergo S-phaseor S-phase
and G2/M-phase delay upon treatment with TK/GCV suicide gene
therapy in several tumor models as a consequence of DNA damage,
however a role for cell cycle control as a part of themechanismof action
of TK/GCV has not been described so far [3,5,7]. Our results show astrong association between S-phase and G2/M-phase delay and
sensitivity toTK/GCV in a panel of pancreatic cancer cell lines. Evidences
of apoptosis induction even in resistant cells suggest that alternative
mechanisms of TK/GCV-induced cytotoxicity might be activated,
although those involving S-phase delay might be more efﬁcient. This
association was recapitulated in a model of treatment-induced
resistance generated by repeated treatments using a non-integrative
gene transfer vector. These results also demonstrate for the ﬁrst time
that prolonged treatment may render cells resistant to TK/GCV
independently of the alterations in TK transgene expression documen-
ted when integrative vectors where used [22,23].
Transcriptomic analysis of sensitive and resistant cells treatedwith
TK/GCV allowed for the identiﬁcation of a series of genes with
differential expression that could be participating in the induction of
resistance. Among these, genes involved in cell cycle control such as
CCNE1, the CDK2 activator cyclin E1, whose activity is instrumental
for the transition from G1 to S phases and for the initiation of DNA
synthesis were found to be deregulated [24]. In our experiments,
CCNE1 expression in treatment-induced resistant cells was reduced
and the exogenous expression of CCNE1, in two TK/GCV resistant cell
lines produced an increase in cell sensitivity to TK/GCV. Regarding the
fact that CCNE1 has also been reported to be involved in the induction
of apoptosis in response to genotoxic insults, the therapeutical
application of CCNE1 as an enhancer of TK/GCV cytotoxicity deserves
further exploration [25,26].
The relationship between GADD45A expression and the response
to genotoxic stress varies according to the cell type and the nature of
the genotoxic insult [27], as well as the functional status of other
genes, such as p21 [28]. Our results showed an association between
higher expression of GADD45A and reduced sensitivity to TK/GCV in
the induced-resistance model and an association between higher
induction of GADD45A in response to treatment and reduced
sensitivity to TK/GCV, when comparing pancreatic cancer cell lines
displaying intrinsic differences in sensitivity to this treatment.
Moreover, ectopic expression of GADD45A in RWP-1 and BxPC-3
cells reduced their sensitivity to TK/GCV. It has been described that
GADD45A can act as chemosensitizer in cells treated with 5-FU,
etoposide and cisplatin [29]. Although this might appear as a
Fig. 6. Effects of pharmacological inhibition of Chk1 activity on TK/GCV response. (A) Time course cell cycle proﬁling of NP-18 cells treatedwith AdTK/GCV alone, or in combinationwith
UCN-01. TK/GCV-induced S-phase accumulation was reduced by UCN-01 treatment, either at low (ID50) or high (300 vp/cell) doses of AdTK. (B) DNA synthesis analysis in NP-18 cells
transduced with 300 vp/cell AdTK during 24 h, starting 24 h after initiation of GCV treatment. Results expressed as percentage of untreated control are means of three independent
experiments±SE. **pb0.01.
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displaying different sensitivities to the therapies, and this can be
determinant to the outcome of combination treatments.
We demonstrate for the ﬁrst time that the Chk1/2-NCdc25A axes
of the DNA damage response are activated upon treatment with TK/
GCV, in a time-dependent manner. Although some authors have
reported some degree of overlapping in the action of these axes, it is
widely accepted that Chk2 is phosphorylated by ATM in response to
DSB whereas Chk1 is phosphorylated by ATR mainly in response to
stalled replication forks [19]. The observation of an early Chk1
phosphorylation (prior to Chk2's), at a time point in which the
fraction of cells having duplicated their genome to generate DSB is
negligible, suggests that these cells are initially responding to a
different lesion apart from the proposed DSB [3,30]. The fact that PPP-
GCV's activity can act as a DNA-polymerase competitive inhibitor,leading to inhibition of DNA synthesis [20], could be the triggering
factor for Chk1 response.
Furthermore, the observation that pharmacological inhibition of
Chk1 activity resulted in partial abrogation of treatment-induced S-
phase delay and DNA synthesis inhibition, as well as in an antagonistic
effect on TK/GCV cytotoxicity in cells undergoing S-phase delay in
response to TK/GCV, suggests that checkpoint activation is needed for
the induction of cytotoxicity at lowdoses of TK/GCV, and that Chk1may
play a key role enhancing it.
Checkpoint inhibition has been assayed as a chemosensitizing
intervention aimed at enhancing the cytotoxicity of DNA damaging
chemotherapeutic agents [31]. The rationale behind this strategy is
the indirect blockade of the DNA repair machinery, which would
render treated cells unable to repair DNA damage thus diminishing
their probability of survival [32,33]. This assumption eludes the fact
Fig. 7. Treatment interaction analysis. Combination indexes for the interaction of AdTK/GCV
andUCN-01 treatments are depicted as a functionof fractional inhibition for resistant (A) and
sensitive (B) cells. A CI value equal to 1 was indicative of additive effect, a value of CIN1was
indicative of antagonism and a value of CIb1 was indicative of supraadditive effect. Results
expressed as mean of three independent experiments±SE.
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damage response, apart from the DNA repair machinery, that might
contribute to the overall cytotoxic effect of the genotoxic agent (for
instance, the cytostatic effect of cell cycle inhibition), might be inhibited.
In this sense, Chk1 inhibitorUCN-01hasbeenassayed as chemosensitizer
for several DNA damaging agents and pathologies [31,32]. McMasters
and collaborators showed a potentiation of TK/GCV-induced cytotoxicity
by high concentrations of UCN-01 in colon cancer cells [34]. In this
setting, though, synergism cannot be exclusively attributed to S-phase
checkpoint abrogation, as at those concentrations UCN-01 is able to
target other kinases such as PKC. Inpancreatic cancer cells, Chk1 inhibitor
PD-321852 has been described to enhance gemcitabine cytotoxicity, but
this effect has been associated to an inhibition of DNA damage repair
protein RAD51, rather than to an inhibition of Chk1 [21]. Taken together,
these results suggest that the paradigm of checkpoint inhibition as
chemosensitizing interventionmightbe farmore complex thanoriginally
thought.
The development of diagnostic and prognostic tools integrating
genomic data and expression of biomarkers of sensitivity or
resistance, and evaluating the functionality of checkpoints in resected
tumor samples might allow for an evidence-based personalized
design of more efﬁcient combination therapies for the treatment of
malignant diseases such as pancreatic cancer.
In conclusion, this study underscores that cell cycle events might
be inﬂuencing the ability of TK/GCV to induce cytotoxicity in
pancreatic cancer cells and identiﬁes molecular features that
condition the cellular response to the treatment. CCNE1 and
GADD45A are validated as conditioners of TK/GCV sensitivity.
Importantly, this study reveals the association of cell cycle checkpoint
pathwayswith themechanism of action of TK/GCV, points out at Chk1
activation as a key factor to mediate TK/GCV cytotoxicity and alerts
that pharmacological inhibition of Chk1 exerts an antagonistic effectin cells sensitive to TK/GCV. These data suggest that the functionality
of S-phase checkpoint in tumor biopsies could have predictive value
in terms of treatment outcome, particularly when TK/GCV could be
applied in combination with other drugs.
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